NCT02921828View on ClinicalTrials.gov

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

CompletedOBSERVATIONAL
Enrollment

1,149

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 10, 2015

Study Completion Date

December 10, 2015

Conditions
Multiple Myeloma
Trial Locations (2)

00000

Local Institution - Japan, No City Provided

651-0072

Shinko Hospital, Kobe

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT02921828 - A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg | Biotech Hunter | Biotech Hunter